Use of anti-my019 antibodies in the diagnosis or screening of seronegative rheumatoid arthritis

By using anti-MYO19 antibody as a biomarker and combining it with protein microarray technology, the challenge of early diagnosis of serum-negative rheumatoid arthritis (RA) has been solved, improving the positive diagnostic rate and reducing the misdiagnosis rate.

CN122410045APending Publication Date: 2026-07-17PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610542601.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-22
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current technology lacks effective diagnostic methods to identify seronegative rheumatoid arthritis (RA), making early diagnosis difficult and missing the optimal treatment window.

Method used

Using anti-MYO19 antibodies as biomarkers, the anti-MYO19 antibodies in the test samples were detected by methods such as protein/peptide chip detection and enzyme-linked immunosorbent assay (ELISA), and verified by protein microarray technology to achieve the diagnosis of serum-negative RA.

Benefits of technology

It improved the diagnostic positivity rate of serum-negative RA from about 70% to 74.5%, providing an early diagnostic tool and reducing the clinical misdiagnosis rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

本发明属于生物检测领域，具体涉及抗MYO19抗体在诊断或筛查血清阴性类风湿关节炎中的应用。本发明首次公开了抗MYO19抗体作为血清阴性类风湿关节炎的诊断或筛查的标志物，通过检测上述标志物的含量可以实现对血清阴性类风湿关节炎的诊断或筛查。
Need to check novelty before this filing date? Find Prior Art